Your browser version may not work well with NCBI's Web applications. More information here...
1: Antimicrob Agents Chemother. 2006 Jun;50(6):2207-9.Click here to read Click here to read Links

Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.

Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ.

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, 94110, USA. sparikh@medsfgh.ucsf.edu

Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.

PMID: 16723585 [PubMed - indexed for MEDLINE]

PMCID: PMC1479139